Discover 1,912 paid clinical trials in Fort Worth, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Fort Worth offers a range of medical research opportunities, focusing on conditions such as cancer, cardiovascular disease, PTSD, and COVID-19. Healthy volunteers looking for paid opportunities, as well as those with specific health concerns, can participate in studies at the city’s leading healthcare facilities, gaining access to new and innovative treatments while contributing to advancements in medical research.
Filter
2
Filter results
Results: 1,912
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
for
Difficult to Control Hypertension
Location: Mansfield TX, Dallas TX, Plano TX, Sherman TX,
Sponsor: E-Star BioTech, LLC
Sex: All
Age: 18 - 70+
Code: NCT06343298
Phase2, Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
for
Inflammatory Bowel Diseases, Crohn's Disease
Location: Mansfield TX, Lewisville TX, Tyler TX, Cedar Park TX,
Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Sex: All
Age: 18 - 70+
Code: NCT06226883
Phase2, Recruiting
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Get alerts for new trials in your area by subscribing now
A Study of DS5361b in Participants With Advanced Solid Tumors
for
Advanced Solid Tumor
Location: Irving TX, San Antonio TX, Sarasota FL, Fairfax VA,
Sponsor: Daiichi Sankyo
Sex: All
Age: 18+
Code: NCT07182591
Phase1, Recruiting
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
for
Major Depressive Disorder (MDD),
Location: Irving TX, Dallas TX, Richardson TX, Chino CA,
Sponsor: Seaport Therapeutics
Sex: All
Age: 18 - 65
Code: NCT07065240
Phase2, Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
for
Breast Cancer, Early Breast Cancer
Location: Irving TX, Pierre SD, Aberdeen SD, Winston-Salem NC
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT05774951
Phase3, Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
for
Prostate Cancer
Location: Irving TX, Houston TX, Merriam KS, St Louis MO,
Sponsor: Amgen
Sex: Male
Age: 18+
Code: NCT04221542
Phase1, Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Location: Irving TX, Waco TX, Austin TX, The Woodlands TX,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07421700
Phase1, Phase2, Recruiting
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
for
Small Cell Lung Cancer (SCLC)
Location: Irving TX, Fredericksburg TX, The Woodlands TX,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07226999
Phase2, Phase3, Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
for
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic,
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
for
Colorectal Neoplasms
Location: Irving TX, Dallas TX, Houston TX, Pueblo CO,
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All
Age: 18+
Code: NCT05253651
Phase3, Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)